Morepen Laboratories
Morepen Laboratories Share Price Chart
Morepen Laboratories last traded at ₹128.12 (2026-10-13). Over the past month the stock moved +11.3%, three months the stock moved +191.4%, year the stock moved +136.6%. Its closing range over 52 weeks is ₹34.18 – ₹146.80, with the latest close 12.7% below the high.
Closing prices up to 2026-10-13.
About Morepen Laboratories
Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.[1]
Market Leadership The company is a leader in the pharmaceutical and medical devices industry, holding the top position in 6 APIs with the following market shares as of H1 FY25: Montelukast (anti-asthmatic): 70% Loratadine (anti-allergy): 69% Desloratadine (anti-allergy): 49% Fexofenadine (anti-allergy): 31% Atorvastatin (cholesterol reducer): 20% Rosuvastatin (cholesterol reducer): 19% Additionally, it is a leader in other products including Sitagliptin, Linagliptin, Dapagliflozin, etc. [1] [2]
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Morepen Laboratories reported sales of ₹570.00 crore (+34.1%) and net profit of ₹56.00 crore (+409.1%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 570.00 | 83.00 | 14.00 | 56.00 | 1.03 |
| Mar 2026 | 485.00 | 24.00 | 5.00 | 16.00 | 0.29 |
| Dec 2025 | 484.00 | 46.00 | 10.00 | 28.00 | 0.50 |
| Sep 2025 | 412.00 | 31.00 | 7.00 | 41.00 | 0.75 |
| Jun 2025 | 425.00 | 24.00 | 6.00 | 11.00 | 0.20 |
| Mar 2025 | 466.00 | 42.00 | 9.00 | 20.00 | 0.37 |
| Dec 2024 | 453.00 | 36.00 | 8.00 | 27.00 | 0.49 |
| Sep 2024 | 438.00 | 44.00 | 10.00 | 35.00 | 0.64 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +3.8% | +1.8% | +10.2% | -6.6% | -5.9% | +6.8% | +4.1% | +34.1% |
| Operating profit growth | +29.4% | -29.4% | -12.5% | -53.8% | -29.5% | +27.8% | -42.9% | +245.8% |
| Net profit growth | +66.7% | -15.6% | -31.0% | -69.4% | +17.1% | +3.7% | -20.0% | +409.1% |
| EPS growth | +52.4% | -22.2% | -32.7% | -71.8% | +17.2% | +2.0% | -21.6% | +415.0% |
| OPM % | 10.0% | 8.0% | 9.0% | 6.0% | 7.0% | 10.0% | 5.0% | 14.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Morepen Laboratories reported sales of ₹1,806.00 crore (-0.3%) and net profit of ₹96.00 crore (-18.6%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 1,806 | 126.00 | 7.00 | 96.00 | 1.73 |
| Mar 2025 | 1,812 | 174.00 | 10.00 | 118.00 | 2.15 |
| Mar 2024 | 1,690 | 159.00 | 9.00 | 97.00 | 1.88 |
| Mar 2023 | 1,418 | 80.00 | 6.00 | 39.00 | 0.76 |
| Mar 2022 | 1,547 | 137.00 | 9.00 | 102.00 | 2.13 |
| Mar 2021 | 1,188 | 119.00 | 10.00 | 97.00 | 2.16 |
| Mar 2020 | 853.00 | 69.00 | 8.00 | 34.00 | 0.75 |
| Mar 2019 | 769.00 | 68.00 | 9.00 | 29.00 | 0.64 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +26.7% | +10.9% | +39.3% | +30.2% | -8.3% | +19.2% | +7.2% | -0.3% |
| Operating profit growth | +4.6% | +1.5% | +72.5% | +15.1% | -41.6% | +98.8% | +9.4% | -27.6% |
| Net profit growth | -3.3% | +17.2% | +185.3% | +5.2% | -61.8% | +148.7% | +21.6% | -18.6% |
| EPS growth | -3.0% | +17.2% | +188.0% | -1.4% | -64.3% | +147.4% | +14.4% | -19.5% |
| OPM % | 9.0% | 8.0% | 10.0% | 9.0% | 6.0% | 9.0% | 10.0% | 7.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Morepen Laboratories.
Get Free AI Stock Analysis FREE →Latest News
-
Morepen Laboratories submits first ANDA to USFDA for Sitagliptin Tablets - Business Standard
-
Morepen Laboratories submits first ANDA to USFDA for Sitagliptin Tablets - Business Standard
-
Morepen climbs on strengthening integrated CDMO capabilities with first U.S. ANDA submission
-
Morepen strengthens integrated CDMO capabilities with first U.S. ANDA submission
-
Morepen Laboratories submits first ANDA to USFDA for Sitagliptin Tablets - Business Standard
-
Morepen Laboratories Completes First Phase Of Manufacturing Expansion; Shares Rise 3.14%
-
Morepen Laboratories successfully completes phase 1 of capacity expansion - Business Standard
-
Morepen Laboratories FY26 Results: standalone sales up 8.39% to ₹1,677 crore - scanx.trade
-
Morepen Laboratories consolidated net profit rises 424.65% in the June 2026 quarter - Business Standard
-
Morepen Laboratories consolidated net profit rises 424.65% in the June 2026 quarter - Business Standard
Frequently Asked Questions
What is the share price of Morepen Laboratories today?
Morepen Laboratories shares were last quoted at ₹128.12 (-1.1% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Morepen Laboratories?
Morepen Laboratories has a price-to-earnings (P/E) ratio of 47.05 and a price-to-book (P/B) ratio of 5.07. The industry P/E is 53.33.
What is the 52-week high and low of Morepen Laboratories?
The 52-week high of Morepen Laboratories is ₹126.90 and the 52-week low is ₹33.44.
What is the market cap of Morepen Laboratories?
The market capitalisation of Morepen Laboratories is about ₹6,600.10 crore.
How did Morepen Laboratories perform in its latest quarterly results?
In the latest quarter (Jun 2026), Morepen Laboratories reported sales of ₹570.00 crore (+34.1%) and net profit of ₹56.00 crore (+409.1%), compared with the same quarter last year.
Is Morepen Laboratories a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Morepen Laboratories has a 3-year ROE of 10.00%, 3-year profit growth of 24.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Morepen Laboratories?
Promoters hold about 35.65% of Morepen Laboratories.
Which sector does Morepen Laboratories belong to?
Morepen Laboratories belongs to the Pharmaceuticals & Drugs sector.